Clinical Trial Update: A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS]) [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase III study evaluating the efficacy, safety, and tolerability of plonmarlimab in relapsed/refractory rheumatic and im…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophagocytic Lymphohistiocytosis
• Macrophage Activation Syndrome

Drugs mentioned

• Plonmarlimab (Plonmarlimab)

Snippet

Sponsor: TJ Biopharma Co., Ltd. | Conditions: Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis | Phase 3 | Status: RECRUITING